HCM stock icon



About: HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Employees: 1,990

Funds holding %
of 6,665 funds
Analysts bullish %
News positive %
of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.12% less ownership

Funds ownership: 1.76% [Q4 2023] → 1.64% (-0.12%) [Q1 2024]

1% less funds holding

Funds holding: 69 [Q4 2023] → 68 (-1) [Q1 2024]

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

14% less capital invested

Capital invested by funds: $278M [Q4 2023] → $240M (-$37.6M) [Q1 2024]

27% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 26

27% less call options, than puts

Call options by funds: $45.4K | Put options by funds: $62.2K

Research analyst outlook

We haven’t received any recent analyst ratings for HCM.

Financial journalist opinion

Based on 8 articles about HCM published over the past 30 days